Hepion provides corporate presentation; no material new financial or clinical data

Hepion Pharmaceuticals, Inc.

Rencofilstat Phase 2b ASCEND-NASH enrolling; AI-POWR platform highlighted.
Phase 2a HCC trial pending; rencofilstat tested in over 425 subjects to date.
Cash of $43.0M as of March 31, 2023; IP extends to at least 2031 with PTE.
Core team previously developed voclosporin (Lupkynis) for lupus nephritis.
Presentation details pipeline, finance, and management; no new clinical results disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.